Background: Drug eluting stents (DES) are the most frequently used
devices during coronary interventions. Bioresorbable vascular scaffold (BVS)
were developed to circumvent some of the limitations of DES. Worldwide, there is
very limited experience with this device. The aim of our study was to see the initial
challenges encountered by a single center while using this new device.
Methods: We implanted a total of 24 BVS in 17 patients. These patients were followed
for a two-year period. All patients received similar, standard of care adjunctive
medical therapy. Clinical conditions that necessitated BVS usage were ST
elevation myocardial infarction (STEMI), Non STEMI and acute coronary syndromes
Results: We encountered a high complication rate. Acute and late scaffold thrombosis was seen in
four patients. Death or major bleeding was not seen. Patients with and without complications were
compared for their coronary artery disease (CAD) risk factors, angiographic characteristics and laboratory
data. No difference was detected in their CAD risk factors or metabolic investigations. In all
patients post dilation after scaffold deployment was not performed as per industry recommendation
at that time.
Conclusion: This small study gives insights into potential challenges that centers may face adapting
this new technology. Larger randomized trials with long-term follow-up are needed.